glp 1 drugs pregnancy Early GLP-1 Drug Use Update GLP-1 drugs and pregnancy: Who
Description
P = .21)
& Liu, F
The overweight and obesity epidemic in the USA today resulted from multiple contributing factors, including genetic, medical, environmental, behavioral, and socioeconomic influences
Pharmacokinetic study Plasma agonist concentration after a single IP injection (24 nmol kg 1 ) was measured with an exendin-4 C-terminus-specific ELISA (Phoenix Pharmaceuticals), a peptide region that does not differ between agonists, hence equally detecting exendin-4 and exendin-phe1 (confirmed by analysis of known concentrations of each agonist)
